These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8105072)

  • 21. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
    Connor EM; Sperling RS; Gelber R; Kiselev P; Scott G; O'Sullivan MJ; VanDyke R; Bey M; Shearer W; Jacobson RL
    N Engl J Med; 1994 Nov; 331(18):1173-80. PubMed ID: 7935654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zidovudine therapy in combination with intravenous immunoglobulin in HIV infected children.
    Croft N; Yap PL; Mok JY; Hague RA; Burns SM
    Scott Med J; 1992 Oct; 37(5):138-41. PubMed ID: 1362818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.
    Vermeulen JN; Prins JM; Bunnik E; Hack CE; Jurriaans S; Miedema F; Lange JM; Schuitemaker H
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1348-53. PubMed ID: 18184076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.
    Montaner JS; Gill J; Singer J; Raboud J; Arseneau R; McLean BD; Schechter MT; Ruedy J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):153-7. PubMed ID: 8680886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
    Fischl MA; Resnick L; Coombs R; Kremer AB; Pottage JC; Fass RJ; Fife KH; Powderly WG; Collier AC; Aspinall RL
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):139-47. PubMed ID: 7905523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Harris DR; Rich K; Meyer WA; Read JS; Moye J; Nugent RP; Korelitz J; Bethel J; Pahwa S
    AIDS; 1999 Jan; 13(1):31-9. PubMed ID: 10207542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience with the use of immune intravenous immunoglobulin in symptomatic children with human immunodeficiency virus infection].
    Jiménez E; Carrer MT; Pérez Dieppa I; Ortiz L; Fernández M
    Bol Asoc Med P R; 1991 Dec; 83(12):538-42. PubMed ID: 1811606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: a retrospective cohort study.
    Huang LC; Myer L; Jaspan HB
    BMC Infect Dis; 2008 Sep; 8():127. PubMed ID: 18811982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; McKinney RE; Nichols S; Mitchell WG; Yogev R; Hutcheon N
    Pediatrics; 1998 Feb; 101(2):214-20. PubMed ID: 9445494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex.
    De Gruttola V; Wulfsohn M; Fischl MA; Tsiatis A
    J Acquir Immune Defic Syndr (1988); 1993 Apr; 6(4):359-65. PubMed ID: 8095980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Korelitz J; Meyer WA; Bethel J; Rich K; Pahwa S; Moye J; Nugent R; Read J
    J Infect Dis; 1997 May; 175(5):1029-38. PubMed ID: 9129063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3.
    Lewi DS; Suleiman JM; Uip DE; Pedro RJ; Souza RA; Suleiman GS; Accetturi C; Leite OM; Abreu WB; Kalichman AO; Moraes-Filho JP; Motti EF; Pecoraro ML; Makurath MR; Nessly ML; Leavitt RY
    Rev Inst Med Trop Sao Paulo; 2000; 42(1):27-36. PubMed ID: 10742724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.